Treatments for lung cancer (including minimally invasive methods)

Series
Pulmonary and airways
Status
Published
Date
Number of report
090

Ask the expert

(we accept only company emails)

The report presents a summary of the reimbursement situation for the use of minimally invasive treatment of lung cancer.

The following procedures will be considered under the scope of analysis:

  • Cryotherapy of lung
  • Microwave ablation of lung
  • Photodynamic therapy of lung
  • Radiofrequency ablation of lung

Open and VATS lobectomy will be considered as a comparator.

The analysis will cover hospital settings and day case.

The only reimbursement within public / statutory health insurance systems is considered.

The report includes essential information about reimbursement and national funding, including:

  • A brief overview of the reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Czech Republic
  • Denmark
  • England (UK)
  • Finland
  • France
  • Germany
  • Hungary
  • Italy
  • Netherlands
  • Norway
  • Romania
  • Russia
  • Sweden
  • Switzerland
  • Turkey

Manufacturers of devices related to treatments for lung cancer include:

  • AngioDynamics (Acculis, NanoKnife)
  • CSA Medical (truFreeze)
  • Biomedical (TATO)
  • Boston Scientific (Ultraflex)
  • BTG (ICEfx, Visual-ICE)  
  • HealthTronics (HealthTronics bought Endocare) (PERCRYO, CRYOCARE, V-PROBE)
  • Erbe Elektromedizin (ERBECRYO 2, Flexible cryoprobe, APC 2, VIO, FiAPC probe)
  • Johnson & Johnson (NEUWAVE)
  • Medtronic (Cool-tip, Evident)
  • MedWaves (AveCure)
  • MOSS S.p.A (Certus)
  • Perseon (MicroThermX)
  • Terumo (TATO, MedSphere)

Table of content is not available at the moment. Report is still ongoing.

28

Aug 2020

In July 2020, the network of European HTA agencies, EUnetHTA, announced a final project plan of the project OTCA25 “Stereotactic Body Radiation Therapy (SBRT) for lung, prostate, and liver cancer.”

Read more

11

Aug 2020

In July 2020, the Austrian Institute for Health Technology Assessment (AIHTA) published five decision support documents. The assessed technologies included implantation of a wireless pulmonary artery pressure sensor in patients with advanced heart failure, intrauterine ultrasound-guided transcervical radiofrequency ablation, percutaneous transvascular implantation of a coronary sinus reducing stent, radiofrequency-induced intravesical chemohyperthermia for non-muscle invasive bladder cancer, and Vascular photodynamic therapy with Padeliporfin (Tookad® solution).

Read more

03

Apr 2020

The report presents a summary of the reimbursement situation for minimally invasive treatment of prostate cancer in Europe. The following procedures are considered under the scope of analysis: high intensity focused ultrasound (HIFU), cryoablation, focal laser ablation, radiofrequency ablation, microwave thermal ablation of the prostate. Open and laparoscopic radical prostatectomy, as well as external radioation therapy and low-dose-rate barchytherapy, are considered as comparators. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Read more

03

Apr 2020

The report presents a summary of the reimbursement situation for the use of minimally invasive treatment of lung cancer in Europe. The following procedures ware considered under the scope of analysis: cryotherapy, microwave ablation, photodynamic therapy, radiofrequency ablation of lung. Open and VATS lobectomy will be considered as a comparator. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Read more

09

Sep 2019

NICE issued a consultation document about safety and efficacy of balloon cryoablation for Barrett’s oesophagus and squamous dysplasia of the oesophagus and balloon dilation for eustachian tube dysfunction which were considered for Interventional Procedures Guidance in development for public consultation until 20 September 2019.

Read more
(we accept only company emails)